Hepatitis C Treatment Snapshots: ledipasvir and sofosbuvir co-formulation

Hepatitis C Treatment Snapshots: ledipasvir and sofosbuvir co-formulation

For a simplified snapshot from TREAT Asia/amfAR on ledipasvir and sofosbuvir co-formulation for the treatment of hepatitis C, please click here.

/ News

Share the Post

Related Posts

BMS’ patent bid for Hep C treatment Daclatasvir Challenged
Hepatitis C vaccine fails to prevent chronic infections
The use of generic DAAs for hepatitis C treatment, Freeman et al 2016
APN+ joins MTAAG in congratulating Malaysia on sofosbuvir compulsory license
Patent Situation of The Key Product For Treatment of Hepatitis C: SOFOSBUVIR – WHO working paper, updated 2015
Pricing of Indian generic sofosbuvir, 30th Jan,2016
Flawed patents on hepatitis C drugs latest to be challenged in global push for access
Pricing and availability of generic Indian Ledipasvir and Sofosbuvir co-formulation as on 26 April 2016